Chemotherapy remains one of oncology's blunter instruments: potent against tumours but indiscriminate enough to damage healthy tissue. Avacta Group, a clinical-stage company on AIM, is trying to sharpen that instrument with pre|CISION — a proprietary chemistry that keeps a toxic payload inert until it reaches the tumour. Over the past two years Avacta has shed its diagnostics operations to concentrate wholly on this science.

The Quick Version

  • Avacta has completed a transition to a pure-play therapeutics company, selling Launch Diagnostics and Coris Bioconcept during 2025.
  • The pre|CISION platform masks a chemotherapy payload with a peptide cleaved only by tumour-associated fibroblast activation protein (FAP).
  • Lead candidate faridoxorubicin (AVA6000) reported a 92% disease control rate and four confirmed partial responses in a 38-patient salivary gland cancer cohort at ASCO 2026.
  • The US FDA has agreed a single pivotal trial design with progression-free survival as the primary endpoint, but Avacta intends to advance only with a partner.
  • The company held £16.9m of cash at 31 December 2025 with runway guided into early Q1 2027; it remains loss-making and reliant on further funding or partnering.

What Avacta Actually Does

Following a multi-year restructuring, Avacta describes itself as a pure-play precision oncology company, developing tumour-activated cancer medicines. In March 2025 it sold Launch Diagnostics (a distribution business) for £12.9m, followed in August 2025 by agreeing to sell Coris Bioconcept SRL for roughly £2.2m including earn-outs — described as the final step in becoming pure-play. Its value now rests entirely on its oncology pipeline.

The pre|CISION Platform, Explained

pre|CISION is a peptide drug conjugate technology attaching a chemotherapy warhead to a short, engineered peptide that masks the drug's activity. The peptide is designed to be cleaved by fibroblast activation protein (FAP), an enzyme elevated in the stroma of many solid tumours but largely absent from healthy adult tissue — so the conjugate circulates inactive and unmasks predominantly where FAP is concentrated, aiming for a wider therapeutic window with fewer off-target toxicities.

The Data: Genuinely Promising, Genuinely Early

At ASCO on 1 June 2026, Avacta presented updated Phase 1a/1b data for faridoxorubicin (previously AVA6000), a FAP-activated form of doxorubicin. In a salivary gland cancer expansion cohort of 38 evaluable patients, the company reported four confirmed partial responses and nine minor responses, with a 92% disease control rate, out of 111 patients dosed across the programme. It cited a recommended expansion dose of 310 mg/m² and toxicity rates lower than historical conventional doxorubicin, including no cardiomyopathy cases.

These are Phase 1 findings from a small, single-arm cohort without a comparator — hypothesis-generating signals, not proof the drug extends survival or will win approval.

The FDA-Agreed Pivotal Design

On 25 June 2026, Avacta announced the FDA had agreed a design for a single pivotal study in salivary gland cancer, using progression-free survival as the sole primary endpoint. Crucially, the company said it intends to progress faridoxorubicin into further clinical development only with the support of a partner — meaning the pivotal trial's start is contingent on a deal that hasn't yet materialised. Separately, authorities agreed to remove a lifetime maximum cumulative dose limit at US sites, reflecting the drug's observed cardiac safety profile.

A second candidate, AVA6103, dosed its first patient in the FOCUS-01 Phase 1 trial in March 2026.

The Numbers

For the year ended 31 December 2025, Avacta reported a net loss from continuing operations of £37.1m and an operating loss of £30.7m, on continuing revenue of just £0.11m. R&D expenditure rose to £18.8m from £14.3m. Cash stood at £16.9m at year-end; following a £10m equity placing in March 2026, the company guided to a cash runway into early Q1 2027, reporting £16.4m of cash in an April 2026 update. A convertible bond was carried at £13.4m at year-end, down from £20.5m after £5.1m of principal repayments.

Risks Worth Weighing

Clinical risk is paramount — early Phase 1 signals frequently fail to replicate in controlled, later-stage trials. Regulatory risk persists even with an agreed design, since agreement on trial structure isn't agreement on approval. Financing risk is acute given a runway guided only into early 2027. Partnering risk is specific and significant, since management has tied pivotal progression to securing a partner that may not appear on acceptable terms. Concentration risk has increased following the diagnostics exit, leaving the equity heavily dependent on a narrow pipeline led by one asset.

What to Watch Next

Maturation of the faridoxorubicin Phase 1b salivary gland cancer data. Announcement of a commercial or development partnership for the lead asset. Initiation of the agreed pivotal trial. Initial clinical data from the AVA6103 FOCUS-01 study, guided for late H2 2026. Further financing or non-dilutive funding events.